Trials / Completed
CompletedNCT00096837
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
An Open-Label Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (planned)
- Sponsor
- Pharmacyclics LLC. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Motexafin Gadolinium Injection |
Timeline
- First posted
- 2004-11-17
- Last updated
- 2006-06-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00096837. Inclusion in this directory is not an endorsement.